About Antares Pharma
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Instruments & Supplies
- Sub-Industry: Health Care Supplies
- Exchange: NASDAQ
- Symbol: ATRS
- CUSIP: 03664210
- Previous Close: $2.47
- 50 Day Moving Average: $2.24
- 200 Day Moving Average: $1.83
- 52-Week Range: $0.67 - $2.67
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -23.70
- P/E Growth: -0.19
- Market Cap: $367.55M
- Outstanding Shares: 155,086,000
- Beta: 0.88
- Net Margins: -53.11%
- Return on Equity: -45.93%
- Return on Assets: -33.43%
Companies Related to Antares Pharma:
- Current Ratio: 2.40%
- Quick Ratio: 2.08%
What is Antares Pharma's stock symbol?
Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."
Where is Antares Pharma's stock going? Where will Antares Pharma's stock price be in 2017?
2 equities research analysts have issued twelve-month target prices for Antares Pharma's shares. Their predictions range from $2.00 to $3.00. On average, they expect Antares Pharma's share price to reach $2.50 in the next twelve months.
When will Antares Pharma announce their earnings?
Antares Pharma is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
Who owns Antares Pharma stock?
Antares Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (8.36%), Armistice Capital LLC (7.09%), Perceptive Advisors LLC (1.88%), Renaissance Technologies LLC (1.84%), Kingdon Capital Management L.L.C. (1.30%) and Rubric Capital Management LP (0.75%). Company insiders that own Antares Pharma stock include Fred M Powell, James E Fickenscher, James E Flynn, Leonard S Jacob, Peter J Graham, Robert F Apple and Robert P Roche Jr.
Who sold Antares Pharma stock? Who is selling Antares Pharma stock?
Antares Pharma's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Armistice Capital LLC, Janus Capital Management LLC, Alyeska Investment Group L.P., J. Goldman & Co LP, Baird Financial Group Inc., National Planning Corp and State Street Corp.
Who bought Antares Pharma stock? Who is buying Antares Pharma stock?
Antares Pharma's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Rubric Capital Management LP, Kingdon Capital Management L.L.C., JW Asset Management LLC, Renaissance Technologies LLC and Oxford Asset Management. Company insiders that have bought Antares Pharma stock in the last two years include Fred M Powell, James E Fickenscher, Leonard S Jacob, Peter J Graham, Robert F Apple and Robert P Roche Jr.
How do I buy Antares Pharma stock?
Shares of Antares Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Antares Pharma stock cost?
One share of Antares Pharma stock can currently be purchased for approximately $2.37.